- WKN: A2DKCH
- ISIN: NL0012169213
- Land: The Netherlands
Nachricht vom 05.10.2021 | 15:20
QIAGEN N.V.: Release of a capital market information
/ share repurchase
Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting
With disclosure dated September 22, 2021, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the beginning of a second tranche of up to USD 19.4 million starting on September 27, 2021 under the share repurchase program originally announced on July 12, 2021.
The number of shares which have been bought back within the framework of such tranche of the share repurchase program in the time period from September 27, 2021 until and including October 1, 2021, amounts to 74,737 shares.
Shares were bought back as follows:
The underlying individual trades are published on the website of QIAGEN N.V. (https://corporate.qiagen.com/investor-relations/stock-information/share-buyback/default.aspx).
The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.
Venlo, 5 October 2021
|5912 PL Venlo|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
02. Dezember 08:28 Volkswagen: Neuer Kurstreiber für die Aktie?!
02. Dezember 08:30 Zalando: Das macht jetzt Hoffnung
02. Dezember 08:30 Hot-Stock der Woche: Das Netflix fürs Kinderzimmer
02. Dezember 09:00 Auch das noch: Apple warnt vor nachlassender iPhone-Nachfrage
02. Dezember 09:35 DAX & Co in Gefahr: Wie immun ist Ihr Depot?
News im Fokus
Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025
01. Dezember 2021, 15:38
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: Bio-Gate AG (von GBC AG): Kaufen
02. Dezember 2021